Lexicon Pharmaceuticals, Inc.
Lexicon Pharmaceuticals, Inc. (LXRX) Stock Overview
Explore Lexicon Pharmaceuticals, Inc.’s financial performance, market position, analyst ratings, and future outlook.
LXRX Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of Lexicon Pharmaceuticals, Inc. (LXRX) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
Our forecasting models predict significant price movements, with a 12-month target of $0.80.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -1.84 and a market capitalization of 323.2M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.
Analyst Recommendations
Price Targets
Company Profile
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in The Woodlands, Texas.
Dr. Michael S. Exton Ph.D.
103
2445 Technology Forest Boulevard, The Woodlands, TX
2000